Eating Disorders and GLP-1 RAs

About this resource

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications
originally developed to treat type 2 diabetes. GLP-1 RAs are now being used as an approved or off-label treatment for weight loss and have been trialled as a treatment for some eating disorders such as binge eating disorder (BED).

There is limited research available to help researchers, clinicians and patients/consumers to understand 
the relationships between GLP-1 RAs and eating disorders. However, it is thought that GLP-1 RAs may 
negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information about GLP-1 RAs as well as their possible interaction with eating disorders including physical and psychological impacts. Practice points are provided for clinicians.

PDF Available ?Yes
Year2025

See also

EDNA Information Sheet - Carers

This information sheet has been developed by Eating Disorders Neurodiversity Australia.

Read more

Issue 71: Diabetes and dieting: Risk factors for eating disorders

Editor’s NoteDiabetes and eating disorders: Dr Beth SheltonDieting and children: Dr Laura HartPart 2: Video interview with Royal Children’s Hospital nurse Claire MayUpcoming events – ANZAED Autumn workshops Editor’s NoteWelcome to a new year and a new start in 2021.

Read more

Getting Help for Someone You Are Worried About

 

Click here to download full size

Read more

Stepped System of Care - Chinese (Simplified)

National Eating Disorders Collaboration (NEDC) 将二十年的各部门及患者亲身体验共识与服务发展整合为阶梯式饮食 
失调护理系统模型(如图1所示)。该模型的目的是描述在有效的饮食失调护理系统中应该具备的组成部分。患有或可能患
有饮食失调的人士及其家人/支持者和社区可能需要在疾病(或可能患病)和康复过程中,以不同的强度或频率获得一系列
不同的服务。这个护理连续过程的进展并非直线单向的,一个人可能需要针对其不断复发的症状接受治疗和支援服务,而
这些服务来自阶梯式护理系统的不同级别和不同的服务提供机构。

Read more